P- 18 TREATMENT WITH BEVACIZUMAB IN HIGH OUTPUT CARDIAC FAILURE DUE TO SEVERE HEPATIC COMPROMISE IN HEREDITARY HEMORRHAGIC TELANGIECTASIA PATIENTS: OBSERVATIONAL COHORT STUDY
Introduction and Objectives: Hereditary Hemorrhagic Telangiectasia (HHT) is an autosomal dominant vascular dysplasia affecting 1/5000 individuals. Epistaxis, mucocutaneous telangiectasias and vascular malformations affecting internal organs (brain, lungs, liver and digestive tract) are hallmarks of...
Main Authors: | Carolina Vazquez, Juan Bandi, Marcelo Serra |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2023-03-01
|
Series: | Annals of Hepatology |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1665268123000261 |
Similar Items
-
Bevacizumab for treating Hereditary Hemorrhagic Telangiectasia patients with severe hepatic involvement or refractory anemia.
by: Carolina Vázquez, et al.
Published: (2020-01-01) -
Systemic bevacizumab for high-output cardiac failure in hereditary hemorrhagic telangiectasia: an international survey of HHT centers
by: Hanny Al-Samkari, et al.
Published: (2019-11-01) -
Utility of bevacizumab in chronic gastrointestinal bleeding in hereditary hemorrhagic telangiectasia
by: A. Gutiérrez-Macías, et al.
Published: (2023-10-01) -
Management of Refractory Gastrointestinal Bleeding in Hereditary Hemorrhagic Telangiectasia with Bevacizumab
by: Muaaz Masood, et al.
Published: (2021-01-01) -
Meta-analysis of efficacy and safety of bevacizumab in the treatment of hereditary hemorrhagic telangiectasia epistaxis
by: Huimin Chen, et al.
Published: (2023-12-01)